SG11202010220QA - Gabaa positive allosteric modulator compounds, methods of making, and uses thereof - Google Patents
Gabaa positive allosteric modulator compounds, methods of making, and uses thereofInfo
- Publication number
- SG11202010220QA SG11202010220QA SG11202010220QA SG11202010220QA SG11202010220QA SG 11202010220Q A SG11202010220Q A SG 11202010220QA SG 11202010220Q A SG11202010220Q A SG 11202010220QA SG 11202010220Q A SG11202010220Q A SG 11202010220QA SG 11202010220Q A SG11202010220Q A SG 11202010220QA
- Authority
- SG
- Singapore
- Prior art keywords
- making
- methods
- positive allosteric
- allosteric modulator
- modulator compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659226P | 2018-04-18 | 2018-04-18 | |
| PCT/US2019/027880 WO2019204446A1 (en) | 2018-04-18 | 2019-04-17 | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010220QA true SG11202010220QA (en) | 2020-11-27 |
Family
ID=68239798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010220QA SG11202010220QA (en) | 2018-04-18 | 2019-04-17 | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11542263B2 (en) |
| EP (1) | EP3781566A4 (en) |
| JP (1) | JP7449272B2 (en) |
| KR (1) | KR20210011921A (en) |
| CN (1) | CN112384513A (en) |
| AU (1) | AU2019255282A1 (en) |
| BR (1) | BR112020021104A2 (en) |
| CA (1) | CA3096890A1 (en) |
| CL (1) | CL2020002663A1 (en) |
| IL (1) | IL278067A (en) |
| MX (1) | MX2020010878A (en) |
| SG (1) | SG11202010220QA (en) |
| TW (1) | TW202012402A (en) |
| WO (1) | WO2019204446A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7449272B2 (en) * | 2018-04-18 | 2024-03-13 | ニューロサイクル・セラピューティクス・インコーポレイテッド | GABAA-positive allosteric modulator compounds, methods of production and uses thereof |
| WO2020191047A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of pain |
| CA3154222A1 (en) * | 2019-10-22 | 2021-04-29 | Matthew TOCZKO | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
| JP2022554159A (en) * | 2019-10-23 | 2022-12-28 | ニューロサイクル・セラピューティクス・インコーポレイテッド | Treatment of epileptic conditions with GABAA receptor modulators |
| US20210401849A1 (en) * | 2020-06-30 | 2021-12-30 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| US6936608B2 (en) * | 2000-11-10 | 2005-08-30 | Merck Sharp & Dohme Ltd. | Imidazo-triazine derivatives as ligands for GABA receptors |
| GB0117277D0 (en) * | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| TWI248936B (en) * | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| SI2300455T1 (en) * | 2008-05-21 | 2017-12-29 | Incyte Holdings Corporation | Salts of 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)- imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide and processes related to preparing the same |
| WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| MX2018009252A (en) * | 2016-01-27 | 2019-01-21 | Univ Zuerich | Use of gabaa receptor modulators for treatment of itch. |
| JP7449272B2 (en) * | 2018-04-18 | 2024-03-13 | ニューロサイクル・セラピューティクス・インコーポレイテッド | GABAA-positive allosteric modulator compounds, methods of production and uses thereof |
-
2019
- 2019-04-17 JP JP2021506619A patent/JP7449272B2/en active Active
- 2019-04-17 MX MX2020010878A patent/MX2020010878A/en unknown
- 2019-04-17 CN CN201980041321.7A patent/CN112384513A/en active Pending
- 2019-04-17 WO PCT/US2019/027880 patent/WO2019204446A1/en active Application Filing
- 2019-04-17 SG SG11202010220QA patent/SG11202010220QA/en unknown
- 2019-04-17 KR KR1020207033073A patent/KR20210011921A/en unknown
- 2019-04-17 BR BR112020021104-4A patent/BR112020021104A2/en unknown
- 2019-04-17 AU AU2019255282A patent/AU2019255282A1/en active Pending
- 2019-04-17 TW TW108113441A patent/TW202012402A/en unknown
- 2019-04-17 CA CA3096890A patent/CA3096890A1/en active Pending
- 2019-04-17 EP EP19788410.9A patent/EP3781566A4/en active Pending
-
2020
- 2020-10-15 IL IL278067A patent/IL278067A/en unknown
- 2020-10-15 CL CL2020002663A patent/CL2020002663A1/en unknown
- 2020-10-16 US US17/072,282 patent/US11542263B2/en active Active
-
2022
- 2022-12-28 US US18/089,661 patent/US20230139418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202012402A (en) | 2020-04-01 |
| BR112020021104A2 (en) | 2021-02-23 |
| JP7449272B2 (en) | 2024-03-13 |
| KR20210011921A (en) | 2021-02-02 |
| JP2021522330A (en) | 2021-08-30 |
| CA3096890A1 (en) | 2019-10-24 |
| CL2020002663A1 (en) | 2021-06-11 |
| IL278067A (en) | 2020-11-30 |
| US20210040103A1 (en) | 2021-02-11 |
| US20230139418A1 (en) | 2023-05-04 |
| WO2019204446A1 (en) | 2019-10-24 |
| EP3781566A1 (en) | 2021-02-24 |
| AU2019255282A1 (en) | 2020-11-05 |
| CN112384513A (en) | 2021-02-19 |
| MX2020010878A (en) | 2021-01-29 |
| US11542263B2 (en) | 2023-01-03 |
| EP3781566A4 (en) | 2022-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278067A (en) | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof | |
| EP3602384A4 (en) | Layered masking of content | |
| IL274570A (en) | Sting modulator compounds, and methods of making and using | |
| EP3463355A4 (en) | Modulators of dux4 for regulation of muscle function | |
| IL268731A (en) | New uses of anti-sirpg antibodies | |
| IL283672A (en) | Modulators of trex1 | |
| IL281492A (en) | Modulators of pnpla3 expression | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| IL304618A (en) | Modulators of pcsk9 expression | |
| GB201806072D0 (en) | Methods of manufacture | |
| EP3609500A4 (en) | Treatment of adipocytes | |
| GB201719639D0 (en) | Setection of biomarkers | |
| EP3427163A4 (en) | Node-centric analysis of dynamic networks | |
| DK3327969T3 (en) | NEW PROCEDURE FOR WIRELESS TRANSMISSION OF DIGITAL SOUND | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| EP3723874A4 (en) | Set of dumbbells | |
| GB201805904D0 (en) | Methods of Manufacture | |
| IL277847A (en) | Modulators of ezh2 expression | |
| HK1226397A1 (en) | Solid forms of an ion channel modulator | |
| EP3368693A4 (en) | Oxyntomodulin analogs and methods of making and using same | |
| IL276107A (en) | Solid forms of fasoracetam | |
| SG11202105136WA (en) | Application of chidamide | |
| EP3843630A4 (en) | Analysing symmetry of limb function | |
| EP4048672A4 (en) | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof | |
| EP3300550A4 (en) | Determination of feedback timing |